About us

Fresenius Kabi at a glance


Our product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.



Fresenius Kabi employs about 35,000 people worldwide.

With our corporate philosophy of "caring for life", we are committed​ to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.

In 2016 the company reported sales of €6 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.


Key Figures

€ in millions20162015Change
Sales 6,007 5,950 1%
EBITDA¹ 1,479 1,446 2%
EBIT¹ 1,224 1,189 3%
Net Income² 716 669 7%
Employees 34,917 33,195 5%


¹ 2015 before special items

² Net income attributable to shareholders of Fresenius Kabi AG; 2015 before special items


Fresenius Kabi business fields

The Fresenius Kabi history

Fresenius Kabi worldwide locations 

Denne hjemmeside anvender cookies.

For at optimere denne hjemmeside for dig som bruger anvender vi de såkaldte cookies. De cookies som lagres, vedrører statistik, formularer og i forbindelse med login. Du kan læse mere om vore cookies på menupunktet Cookiepolitik

Ved at klikke på "Fortsæt" godkender du anvendelsen af cookies.

Hvis ikke du kan acceptere, at der bliver lagret cookies, må du forlade hjemmesiden.

  • Sweden Norway Finland